Non-resident patients can access clinical trials for melanoma drugs in Spain if they meet strict eligibility criteria. Major research centers in Madrid and Barcelona frequently enroll international participants for phase 1-3 trials. Patients must usually cover travel, diagnostics, and lodging expenses while study medications are provided at no cost.
- Eligibility requirements: Patients must match specific biomarkers like BRAF mutations for target therapies.
- Research institutions: Quironsalud Madrid and Hospital Quiron Barcelona lead intensive melanoma research programs.
- Specialist expertise: Dr. Jesus Soberino has led numerous trials for pembrolizumab and combination immunotherapies.
- Regulatory pathways: Patients may access unregistered drugs through Spanish Agency of Medicines (AEMPS) programs.
Bookimed Expert Insight: Spanish oncology centers like Clinica Universidad de Navarra maintain exceptionally high international patient volumes, treating over 700,000 people from 70 countries. Our data shows that while trials offer the drug for free, pre-trial diagnostics in Spain can be significant. For instance, immunotherapy packages at top clinics like Teknon Medical Center start around $13,400 just for the medication and basic staging. Always confirm if the trial covers PET-CT and BRAF gene mutation testing, as these costs typically fall on the patient.
Patient Consensus: Patients note that non-EU residents often face bureaucractic hurdles with medical visas. Many recommend budgeting between $5,500 and $16,000 for initial workups and local advocacy to improve enrollment chances.